IRI names Richard Lenny chairman
CHICAGO — IRI on Tuesday named Richard Lenny chairman of its board of directors. Lenny succeeds Lawrence Benjamin, who will remain a member of the board and a senior adviser.
“I am deeply appreciative to Larry for his personal guidance, tremendous contributions to IRI and his continued involvement on the board and support of the business,” stated Andrew Appel, IRI president and CEO. “During the past two years, Larry has made a significant impact on our business through his tireless energy and passionate focus on our retailer and manufacturer clients.”
“Rick brings to IRI an impressive background, including more than three decades of experience in the consumer packaged goods arena, and we are thrilled to have him picking up the torch and helping us drive our ‘Growth Delivered’ strategy forward,” Appel added. “His experience with the client side of our business and resounding track record of leadership success will provide unique perspective to help us accomplish our most critical objectives and exceed our clients’ expectations.”
Lenny previously served as chairman, president and CEO of Hershey Co. Prior to Hershey, Lenny was president of Nabisco Biscuit Co. When acquired by Kraft in 2000, Lenny was named group VP Kraft Foods and president of Nabisco Biscuit and Snacks.
Lenny joined Nabisco in 1998 from Pillsbury Co., where he was president of Pillsbury, North America. Prior to this, he spent 18 years at Kraft Foods, where he held a number of senior marketing and sales positions.
Lenny is a graduate of Northwestern University’s Kellogg School of Management and holds an MBA with honors in marketing and finance, as well as a bachelor’s degree in marketing, magna cum laude, from Georgia State University, which named Lenny to its 2007 Business Hall of Fame and awarded him the 2005 Alumni Achievement Award.
Lenny currently serves on the board of directors of McDonald’s Corp., Discover Financial Services and ConAgra Foods. Lenny previously served on the board of directors of Sunoco and also was chairman of the board of the Grocery Manufacturers Association and chaired its executive committee. In 2008, he received GMA’s Hall of Achievement award.
Global skin care brand Indeed Laboratories makes U.S. retail debut at Walgreens, Duane Reade
NEW YORK & DEERFIELD, Ill. — Skin care brand Indeed Laboratories is bringing its nanoblur and snoxin skin care products to the U.S. market, through distributor Boots USA, with exclusive availability at Walgreens and Duane Reade stores. The brand’s U.S. retail launch is the result of the partnership formed last summer between Alliance Boots and Walgreens.
“Walgreens selected Indeed Laboratories products because they complement our approach to bringing our customer the proven innovation she seeks,” stated Shannon Curtin, Walgreens divisional VP and GMM of beauty and personal care. “Shoppers know that they can always find the latest skincare items at Walgreens, and now that includes nanoblur and snoxin. Our knowledgeable beauty advisors are available to help answer any questions on these new products.”
Indeed Laboratories was founded from a simple idea put forth by Dia Foley, VP sales and marketing of Indeed Laboratories, who has been with the company from the start and has more than 20 years of experience in the beauty industry. As a spokesperson for many top cosmetic brands, she was constantly in front of cameras and concerned about how her skin was appearing on screen. Foley’s goal was to achieve that soft, camera lens filter effect directly onto the surface of the face for an instant result. Out of the need for instant, flawless, HD-ready skin, nanoblur instant skin perfector was born. Since breaking onto the beauty scene the company has introduced a range of skin care solutions to women across the globe, with current distribution in the United Kingdom, Canada, South Africa, Asia, Australia and New Zealand.
One of the first products to be available in the United States is nanoblur. In the United Kingdom, nanoblur experienced unprecedented sales in its first week in participating Boots locations. Indeed, Laboratories and Walgreens aim to repeat this success in the United States with the exclusive launch of nanoblur instant skin perfector and snoxin facial line fighter beginning this month.
“Based upon the great success that Boots experienced with Indeed Laboratories in the United Kingdom, we’re thrilled to work with Indeed to bring their great products to launch exclusively in Walgreens and Duane Reade in the United States,” added Gordon Farquhar, managing director for Boots Retail USA. “With the help of Walgreens and Indeed Laboratories products, women have access to innovative and affordable beauty solutions that deliver great results.”
Indeed Laboratories’ line of products includes:
Nanoblur Instant Skin Perfector (MSRP: $19.99) gives high-definition camera-ready skin in seconds. Nanoblur instantly transforms skin, minimizing the signs of aging — smoothing and softening the appearance of fine lines, wrinkles, crow’s feet, enlarged pores, uneven texture and tone while mattifying skin. This instant skin perfecting cream is colorless, making it perfect for both women and men. Nanoblur was the first-to-market instant skin perfector that may be worn without, applied under, mixed with or applied over makeup, making it unique and in its own category.
Snoxin Facial Line Fighter (MSRP: $29.99) is a concentrated multipeptide facial serum designed to help combat the appearance of skin aging in the long term. Snoxin incorporates multiple peptides for reducing the appearance of lines, wrinkles and crow’s feet, and provides visible results in seven days, according to the manufacturer.
Lupin wins approval for generic diabetes drug
MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Lupin, the company said.
Lupin, based in India, received approval for metformin hydrochloride extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is a generic version of Santarus’ Glumetza.
Glumetza had sales of about $144 million during the 12-month period that ended in March, according to IMS Health. The drug is an extended-release formulation of metformin hydrochloride, a widely prescribed drug used for treating Type 2 diabetes.